Entering text into the input field will update the search result below

BrainStorm Cell recruits manufacturing partner for stem cell therapies for neurodegenerative disorders

Oct. 26, 2020 3:09 PM ETBrainstorm Cell Therapeutics Inc. (BCLI) StockBCLIBy: Meghavi Singh, SA News Editor
  • BrainStorm Cell Therapeutics (BCLI -5.0%) partners with Rapid Reshore & Development (RR&D) to expedite site selection and design services for a manufacturing facility for NurOwn in the U.S.
  • The ~50K-square foot building will contain manufacturing suites, and the ability to expand the facility to 100K square feet to anticipate future needs.
  • NurOwn technology platform is used to produce autologous MSC-NTF cells, which have received Orphan Drug status in the U.S. and Europe for the treatment of amyotrophic lateral sclerosis (ALS).
  • Phase 3 trial in ALS is fully enrolled, and is investigating repeat administration of autologous MSC-NTF cells. Recently, the company completed enrollment in Phase 2 trial in progressive multiple sclerosis.

Recommended For You

More Trending News

About BCLI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BCLI--
Brainstorm Cell Therapeutics Inc.